MTHFR基因多态性与结肠癌患者术后FOLFOX4辅助化疗疗效的关系

目的研究亚甲基四氢叶酸还原酶基因(MTHFR)C677T多态性与结肠癌术后患者接受FOLFOX4辅助化疗疗效的关系。方法对行结肠癌根治术后接受FOLFOX4方案化疗6周期的76例患者，采用焦磷酸测序法检测MTHFR C677T 基因多态。结果76例Ⅱ、Ⅲ期结肠癌患者的MTHFR-C677T位点存在3种等位基因型，其基因频率分别为：C/C 47.4%（36/76），T/C40.8%（31/76），T/T11.8%（9/76）。C/C 基因型36例中复发11例，T/C基因型31例中复发13例，T/T基因型9例中复发2例，T/T基因型复发比率小于C/C+ T/C基因型（22.2% vs.35.8%），但差异无统计学意义（P=0.710）。结论MTHFR-C677T基因多态性与结肠癌FOLFOX4辅助化疗疗效无关。

Relationship between Polymorphism of MTHFR and Curative Effect of FOLFOX4 Adjuvant Chemotherapy in Postoperative Colon Cancer Patients

ObjectiveTo study the relationship between polymorphism of methylenetetrahydrofolate reductase (MTHFR) and FOLFOX4 adjuvant chemotherapy in postoperative colon cancer patients.MethodsA total of 76 postoperative colon cancer patients were enrolled and recived six cycles of FOLFOX4 adjuvant chemotherapy MTHFR C677T gene polymorphism was detected by pyrophosphoric acid sequencing method.ResultsThe three allelotypes of the MTHFR-C677T in 76 patients were C/C 47.4%（36/76）, T/C40.8%（31/76）, T/T11.8%（9/76）. The relapsed cases were 11 in C/C, 13 in T/C, 9 in T/T.The relapsed rate in T/T was similar to C/C and T/C (P=0.710).ConclusionThere had no relationship between MTHFR C677T mutation and curative effect of FOLFOX4 adjuvantchemotherapy in postoperative colon cancer patients.